Global Colon Cancer Association (GCCA), shared on LinkedIn:
“What’s next for MSS colorectal cancer? Phase 3 trials are bringing fresh momentum to the research landscape.
Microsatellite stable (MSS) colorectal cancer accounts for roughly 85% of colorectal cancer cases, yet immunotherapy alone has rarely worked for this group.
Now, a growing number of Phase 3 clinical trials are testing new approaches, from combinations of immunotherapy and chemotherapy to treatments targeting specific tumor markers.
Biomarker testing and timing matter. Some trials are only open to people who have not yet started treatment for metastatic disease.
Knowing your biomarker status early can help patients and their care teams explore relevant treatment options and clinical trials.
Explore the latest research, key trials, and questions to ask your care team in our new blog post.”
Other articles about Colorectal Cancer on OncoDaily.